ELSEVIER
Contents lists available at ScienceDirect
Seminars in Oncology
journal homepage: www.elsevier.com/locate/seminoncol
Seminars in Oncology
me3Rx-$$ E-mc2
-
Me-Too Therapies in Cancer, Part 1
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab
Check for updates
R.T. Caseya,b,*, O. Giger, I. Seethoa, A. Marker, D. Pitfielda, L.H. Boyled, M. Gurnella, A. Shawe, M. Tischkowitzb, E.R. Maherb, V.K. Chatterjeeª, T. Janowitzf, G. Mells &, P. Corrief, B.G. Challisa,h,*
a Department of Endocrinology and Diabetes, Cambridge University NHS Foundation Trust, Cambridge, UK
b Department of Medical Genetics, Cambridge University, Cambridge, UK
“Department of Histopathology, Cambridge University NHS Foundation Trust, Cambridge, UK
d Department of Pathology, University of Cambridge, Cambridge, UK
e Department of Radiology, Cambridge University NHS Foundation Trust, Cambridge, UK
f Department of Medical Oncology, Cambridge University NHS Foundation Trust, Cambridge, UK % Department of Hepatology, Cambridge University NHS Foundation Trust, Cambridge, UK
h IMED Biotech Unit, Clinical Discovery Unit, AstraZeneca, Cambridge, UK
ARTICLE INFO
Article history: Received 31 May 2018 Accepted 7 June 2018
Keywords: Adrenocortical carcinoma Lynch syndrome Cortisol Pembrolizumab Hepatitis
ABSTRACT
Context: Metastatic adrenocortical carcinoma (ACC) is an aggressive malignancy with a poor prognosis and limited therapeutic options. A subset of ACC is due to Lynch syndrome, an inherited tumor syndrome resulting from germline mutations in mismatch repair (MMR) genes. It has been demonstrated that sev- eral cancers characterized by MMR deficiency are sensitive to immune checkpoint inhibitors that target PD-1. Here, we provide the first report of PD-1 blockade with pembrolizumab in a patient with Lynch syndrome and progressive cortisol-secreting metastatic ACC.
Case report: A 58-year-old female with known Lynch syndrome presented with severe Cushing’s syn- drome and was diagnosed with a cortisol-secreting ACC. Three months following surgical resection and adjuvant mitotane therapy the patient developed metastatic disease and persistent hypercortisolemia. She commenced pembrolizumab, but her second cycle was delayed due to a transient transaminitis. Com- puted tomography performed after 12 weeks and 2 cycles of pembrolizumab administration revealed significant disease progression and treatment was discontinued. After 7 weeks, the patient became jaun- diced and soon died due to fulminant liver failure.
Conclusion: Treatment of MMR-deficient cortisol-secreting ACC with pembrolizumab may be ineffec- tive due to supraphysiological levels of circulating corticosteroids, which may in turn mask severe drug- induced organ damage.
@ 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)
Introduction
Adrenocortical carcinoma (ACC) is a rare and aggressive can- cer with limited therapeutic options for patients with advanced disease. In adults, the majority of ACC are sporadic; however, it is recognized that a subset of ACC is associated with Lynch syndrome, an autosomal dominant tumor syndrome caused by pathogenic mutations of DNA mismatch repair (MMR) genes
(MSH2, MSH6, PMS2, and MLH1) [1,2]. MMR-deficient tumors possess a high somatic mutation burden and present a diverse repertoire of neoantigens which in turn enhances tumor immuno- genicity and thus tumor-specific T cell responses. This is relevant in the context of the important advances in T cell immune check- point targeted cancer immunotherapy, in particular with drugs that target programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of tumor cells and inhibits T cell activation through binding of its cognate coinhibitory T cell receptor, PD-1. In many tumors, PD-L1 expression is upregulated, enabling tumor cells to evade the host immune system through inhibition of activated T cells. Immune checkpoint inhibitors that target this pathway, by blocking either PD-1 or PD-L1, have led to significant clinical responses in some patients with different cancer types [3]. Indeed,
* Corresponding authors. Department of Endocrinology & Diabetes, Cam- bridge University NHS Foundation Trust, Cambridge, UK. Tel .: +44 1223217848; fax: +44 1223217080.
E-mail addresses: rc674@medschl.cam.ac.uk (R.T. Casey),
bc340@medschl.cam.ac.uk (B.G. Challis).
https://doi.org/10.1053/j.seminoncol.2018.06.001
recent landmark studies have now demonstrated that MMR- deficient tumors are more responsive to PD-1 blockade with the anti-PD-1 antibody pembrolizumab than MMR-proficient tumors, with response rates exceeding 50% [4]. Based on these data, pem- brolizumab was granted Food and Drug Administration approval for the treatment of unresectable or metastatic, microsatellite instability-high (MSI-H) or MMR-deficient solid tumors regard- less of tumor site or histology. One of the limitations of T cell checkpoint targeted cancer immunotherapy are T cell mediated autoimmune side effects, that can be severe and life threatening, but can be ameliorated with immune suppressive medications, such as glucocorticoids [5]. This demonstrates that the enhanced T cell response may be sensitive to or prevented by the high levels of cortisol that are found in patients with cortisol secreting ACC.
Here, we describe the first reported case of a cortisol-secreting metastatic ACC treated with pembrolizumab in a patient with Lynch syndrome.
Methods and materials
MMR immunohistochemistry was performed using the Ven- tana Benchmark MMR panel: MLH-1 (M1), PMS2 (EPR3947), MSH2 (G219-1129), and CONFIRM anti-MSH6. PD-L1 immunohistochem- istry was performed using the PD-L1 IHC 22C3 pharmDx test (Dako) and 2-microglobulin immunohistochemistry was per- formed using a polyclonal rabbit antihuman antibody (Dako, Cat# A0072). Immunohistochemistry was performed on 4 um sections of paraffin embedded tumor tissue, in accordance with the manu- facturer’s guidelines and interpreted by an experienced pathologist (OG).
Results and clinical case description
A 58-year-old female presented with a 2 year history of pro- gressive weight gain and reduced mobility. Her medical history was significant for Lynch syndrome due to a pathogenic mutation in MSH2 (p.Asn263fs). The patient had previously undergone an abdominal hysterectomy and bilateral salpingo-oophorectomy fol- lowing identification of cervical cell dysplasia. Annual colonoscopic examinations were normal. There was no history of glucocorticoid exposure. Clinically, the patient was hypertensive (165/130 mmHg) with an elevated body mass index (30 kg/m2). She was hirsute, profoundly plethoric with widespread ecchymoses and exhibited a marked proximal myopathy. Abdominal examination revealed vi- olaceous abdominal striae, in the absence of any organomegaly or palpable masses. Biochemical investigations revealed marked autonomous adrenocorticotrophic hormone-independent hypercor- tisolemia (urinary free cortisol 1870 nmol/24 h [normal range: <146 nmol/24 h]; adrenocorticotrophic hormone < 5 ng/L (nor- mal range: < 50 ng/L)) (Fig. 1A) and hyperandrogenism (testos- terone 4.8 nmol/L [normal range: 0.2-3 nmol/L]); androstenedione 22.7 nmol/L [normal range: 1.4-4.3 nmol/L]). Computed tomogra- phy (CT) demonstrated an 11 cm x 7 cm heterogeneous lesion aris- ing from the left adrenal and no evidence of metastatic disease (Fig. 1B).
The patient underwent an uncomplicated left adrenalectomy and nephrectomy. Subsequent pathological examination of the re- sected tumor confirmed a stage III ACC (modified Weiss Score 9). Few tumor infiltrating lymphocytes were identified and tumor PD-L1 expression was low (<1%) (Fig. 2A and B). Immunohisto- chemical analysis of the tumor demonstrated an isolated loss of MSH2 and MSH6 expression with preserved expression of MLH1 and PMS2 (Fig. 2C-F). Adjuvant mitotane therapy (up to a maxi- mum tolerated dose of 2,000 mg each day) was commenced with concomitant hydrocortisone replacement therapy (40 mg daily in divided doses).
Three months following surgery the patient developed wors- ening abdominal pain. CT revealed tumor recurrence in the left adrenal bed and new hepatic metastases (Fig. 1B). In view of disease recurrence in the context of a MMR-deficient tumor, the patient was commenced on pembrolizumab (2 mg/kg) in com- bination with mitotane (2,000 mg daily). Following the first cy- cle of pembrolizumab, the patient developed a mild elevation of serum alanine aminotransferase (peak ALT 208 U/L [normal range: 7-40 U/L]). Since the differential diagnosis for the eleva- tion of serum ALT included mitotane-induced hepatotoxicity and immunotherapy-induced autoimmune hepatitis, mitotane was dis- continued and the second cycle of pembrolizumab was delayed. Within 14 days of discontinuing mitotane, liver function had im- proved (ALT 129 U/L) and continued to do so when assessed 9 days later (ALT 70 U/L). During this period metyrapone was commenced at a dose of 2,000 mg per day; however, a 24 hour urinary cor- tisol rose to 1,066 nmol/24 h (Fig. 1A). Metyrapone was further increased to 3,000 mg daily and the patient proceeded to receive a second cycle of pembrolizumab without any further disturbance in liver function tests, although treatment tolerance was poor, due to nausea, vomiting, and fatigue. Twelve weeks following initiation of treatment, CT imaging revealed significant disease progression, with both rapidly increased size of the relapsed disease at the pri- mary site and multiple new liver metastases (Fig. 1B).
The clinical management was changed to focus on best supportive care and pembrolizumab treatment was, therefore, discontinued. Seven weeks later, the patient was admitted to hospital, grossly jaundiced (bilirubin 371 umol/L [normal range: 0-20 umol/L]). Biochemical indices of liver function were markedly deranged with ALT 1,553 U/L (normal range: 7-40 U/L); alkaline phosphatase 530 U/L (normal range: 30-130 U/L); and interna- tional normalized ratio (3.7; Fig. 1A). Liver ultrasound showed only limited increase in size of liver metastases with no new lesions identified. Viral hepatitis serology was negative. A liver biopsy was not feasible due to the presence of coagulopathy and rapid clinical deterioration. The possibility of pembrolizumab-induced autoim- mune hepatitis could not be excluded, so methylprednisolone (2 mg/kg) and mycophenolate mofetil (500 mg twice daily) were commenced. However, the patient developed fulminant liver fail- ure and died 3 days later. Both the family and coroner declined post mortem examination.
Discussion
In 2017, the Food and Drug Administration granted accelerated approval for pembrolizumab use in any solid tumor shown to be MSI-high or MMR-deficient. This decision was based on clinical trial data demonstrating high response rates in patients with ad- vanced cancer whose tumors had these genetic signatures [4,6]. Most of the patients had received multiple preceding lines of treat- ment. In their most recent study, Le et al investigated the efficacy of pembrolizumab in patients with progressive MMR-deficient tu- mors across 12 different cancer types, and reported an objective response rate of 53% [4].
ACC was not represented in these initial studies, but is a recognized Lynch syndrome associated malignancy [1,2]. Whether sporadic or associated with an inherited tumor syndrome, the standard treatment for patients with good performance status and unresectable or metastatic ACC is currently combination chemotherapy consisting of etoposide, doxorubicin, cisplatin, and mitotane. Unfortunately, this combination therapy is associated with dose - limiting side effects and serious adverse events, while only resulting in a modest improvement in median overall survival [7]. Therefore, there remains an unmet therapeutic need for patients with advanced ACC. That MMR-deficient cancers are sensitive to immune checkpoint blockade provides a potential
A
Cycle 1 pembrolizumab + mitotane
Cycle 2 pembrolizumab + metyrapone
Terminal admission
Diagnosis
2000
Surgery + mitotane
Mitotane stopped & metyrapone started
1750
1500
Urinary free cortisol (nmol/24 hours)
1500
1250
1000
ALT (U/L)
1000
750
500
500
250
0
1
0
0
100
200
B
Time (days)
0
0
Day 0
Day 91
Day 180
precision medicine opportunity for the relevant subset of patients with ACC.
Immune checkpoint inhibitors are significantly improving clin- ical outcomes in some advanced cancers, although most patients progress with their disease despite treatment. Both primary and acquired resistance mechanisms have been described, and may be secondary to the intrinsic and extrinsic factors to tumor cells [3,8,9]. One of the cancer cell intrinsic immune escape mechanisms is impaired antigen presentation by cancer cells due to reduced expression of peptide-MHC processing components [3]. In our pa- tient’s primary tumor, we found preserved 2-microglobulin ex- pression, with a distinct membranous staining pattern within the parenchyma (Fig. 2G). While this is not a comprehensive assess- ment of the antigen processing pathway, these data suggest that other mechanisms may account for the immunotherapy failure we observed. As such, the impact of systemic glucocorticoid exposure on immunotherapy responsiveness should be considered, but is in- completely understood [10]. The case we describe provides a rare opportunity to examine the relationship of systemic immune sup- pression with increased MMR-deficiency mediated cancer cell anti- genicity in the context of cancer immunotherapy.
Glucocorticoids regulate many aspects of immune function, in- cluding suppression of the cellular Th1 immune responses that are ostensibly required for the antitumor effects of immune checkpoint inhibitors. Indeed, preclinical studies in a rodent model of pan-
creatic ductal adenocarcinoma demonstrated that elevated plasma corticosterone levels impaired immunotherapy outcome [11]. The resected ACC tumor in the case described here was character- ized by a paucity of tumor infiltrating T lymphocytes. Typically, MMR-deficient tumors display an increased number of lympho- cytes within the tumor which correlates with response to immune checkpoint inhibition and prognosis [3]. The discordance between these findings and our case may reflect the suppressive effects of glucocorticoids on T cell chemotaxis and migration, possibly poten- tiated by the high local concentration in the tumor microenviron- ment, and, at least in part, explains the poor response to immune checkpoint blockade. Glucocorticoids have also been shown to in- duce Fas-L overexpression in preclinical models of ACC, suggesting existence of additional glucocorticoid-regulated mechanisms that may impair response to immunotherapy [12]. Furthermore, our case demonstrates the potential for fluctuating levels of endoge- nous glucocorticoids to potentially influence response to immune- related adverse events.
The patient described in this report developed transient liver dysfunction after the first cycle of pembrolizumab. Immunotherapy with pembrolizumab was discontinued after cycle 2 due to rapid disease progression. The patient developed fatal liver failure that did not respond to treatment with immune suppression 7 weeks after stopping pembrolizumab. Hepatitis is a recognized immune- related adverse event associated with pembrolizumab, occurring
A
B
C
D
E
F
G
in approximately 1% of all treated patients. Higher rates of liver damage have been reported when potentially hepatotoxic agents, such as dacarbazine, are given in combination with checkpoint inhibitors [13]. We speculate that concurrent treatment with the hepatotoxic agents, mitotane and metyrapone, may have increased the risk of liver injury, but cannot completely exclude the possibil- ity that liver failure was due to disease progression. It is notable that conflicting data exist whether the occurrence of immune- related adverse events are associated with improved response to treatment [14]. This again could be reflective of the pretreatment state of T cell infiltration into tumor and normal tissue. In the case discussed here, it is conceivable that the very high intratumoral cortisol concentration may have caused a more profound intra- tumoral immune suppression when compared to the liver tissue. This could have reduced the therapeutic index and caused pem- brolizumab toxicity in the absence of antitumor efficacy.
Glucocorticoids are the mainstay of treatment for immune- related adverse events, and to date, there is no evidence that
their use once the effect of immunotherapy has been es- tablished impacts upon treatment outcomes. However, in this case glucocorticoids were elevated when treatment commenced, which represents a distinct clinical scenario. Our report high- lights a need for further investigations to determine whether supraphysiological concentrations of glucocorticoid (endogenous or exogenous) induce a degree of systemic immunosuppres- sion that impacts upon clinical response to immune checkpoint inhibition.
In summary, we report the first description of pembrolizumab treatment in a MMR-deficient and cortisol-secreting metastatic ACC. The therapy was not effective and rapid disease progression occurred. Although no single case should be used to argue against recommendations based on comprehensive scientific and clinical investigation, it is important to acknowledge potential immuno- suppressive phenomena that may reduce the efficacy of cancer immunotherapy, and cases can serve as a salutary reminder that there can be exceptions to the rule.
Funding
RC receives funding from the HRB (Ireland). LHB is funded by a Wellcome Trust Senior Research Fellowship(104647). TJ is supported by a Cancer Research UK Clinician Scientist grant (C42738/A24868).
Disclosure
BGC is an employee of AstraZeneca.
References
[1] Raymond VM, Everett JN, Furtado LV, et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol 2013;31:3012-18.
[2] Challis BG, Kandasamy N, Powlson AS, et al. Familial adrenocortical car- cinoma in association with lynch syndrome. J Clin Endocrinol Metab 2016; 101:2269-72.
[3] Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541:321-30.
[4] Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts re- sponse of solid tumors to PD-1 blockade. Science 2017;357:409-13.
[5] Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the practitioner. J Clin Oncol 2015;33:2092-9.
[6] Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
[7] Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in ad- vanced adrenocortical carcinoma. N Engl J Med 2012;366:2189-97.
[8] Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 2018; 118:9-16.
[9] Flint TR, Fearon DT, Janowitz T. Connecting the metabolic and immune re- sponses to cancer. Trends Mol Med 2017;23:451-64.
[10] Connell CM, Raby SEM, Beh I, et al. Cancer immunotherapy trials underutilize immune response monitoring. Oncologist 2018;23:116-17.
[11] Flint TR, Janowitz T, Connell CM, et al. Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab 2016;24:672-84.
[12] Wolkersdorfer GW, Marx C, Lohmann T, et al. The mercy of adrenocortical tu- mor cells on lymphocytes. Endocr Res 1998;24:711-16.
[13] Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for pre- viously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
[14] Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associ- ated with immune checkpoint blockade. N Engl J Med 2018;378:158-68.